Filter By Industry
Filter By Tag

Newsroom

BHV Pharma Press releases

1 - 2 of 2 Press Releases

SGLT2 Inhibitor Remogliflozin-Etabonate Shows No Reduction in Efficacy in Renally Impaired Subjects
Oct 03, 2013
Clinical Study of SGLT2 Inhibitor Remogliflozin-Etabonate Demonstrates No Reduction in Effectiveness in Renally Impaired Subjects

BHV Pharma Announces Completion of Clinical Study of SGLT2 Inhibitor Remogliflozin Etabonate
Dec 27, 2011
Clinical Study of SGLT2 Inhibitor Remogliflozin Etabonate Demonstrates Effectiveness of Novel Once-Daily Formulation


BHV Pharma RSS Feed